Restoration of defective EA(G)-rosetting capacity of cancer patient neutrophils by levamisole

F. Patrone, F. Dallegri, V. Pistoia

Research output: Contribution to journalArticlepeer-review

Abstract

Levamisole, used in vitro at therapeutic concentrations, was found able to restore the defective Fc-receptor activity of cancer patient neutrophils. In addition, the drug prevented the inhibition of normal neutrophils Fc-receptor function by cancer patient sera. The neutrophil Fc-receptor function was also restored in six of seven cancer patients after in vivo administration of levamisole (2.5 mg/Kg/day for 3 days). Due to the central role played by the Fc-receptor function in host defence mechanisms, including phagocytosis as well as antibody dependent cellular cytotoxicity, the capacity of levamisole to restore defective neutrophil Fc-receptor function in cancer patients could contribute to the 'immunomodulating' effect of the drug.

Original languageEnglish
Pages (from-to)1668-1672
Number of pages5
JournalCancer
Volume55
Issue number8
Publication statusPublished - 1985

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Restoration of defective EA(G)-rosetting capacity of cancer patient neutrophils by levamisole'. Together they form a unique fingerprint.

Cite this